Thyas has raised JPY 240 million in Series A2 financing on November 20, with participation from Kyoto University Innovation Capital Co., Ltd., Chushin Venture Capital Co., Ltd., and Future Venture Capital Co., Ltd.

The funds will be used for accelerating the research and development including preclinical studies of iPS cell-derived T cell therapy for the treatment of solid cancers.